MagicMed Shortcuts Commercialization Timeline with University Agreement

Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations for certain therapies targeting life-threatening conditions.

MagicMed Industries Inc., a developer of licensable psychedelic molecular derivatives, shortcut its commercialization timeline via a Research Contract and Facilities Use Agreement with the University of Calgary to support the development of its PsybraryTM.

Let’s take a closer look at this agreement and what it means for the company as it gears up to go public in the middle of next year.

Agreement Provides Research Support

MagicMed has been focused on the development of the PsybraryTM, a library of psychedelic molecular derivatives that it hopes to license to partners to commercialize. Since these molecules are patentable—unlike natural compounds—with unique properties, they are ideally suited for pharmaceutical companies to develop into psychedelic-based mental health therapies.

The company’s recent agreement with the University of Calgary will provide it with further scientific and laboratory support to accelerate development of the PsybraryTM and shortcut its commercialization timeline. Through the agreement, the company will be able to leverage new state of the art equipment and draw upon world-class expertise at the university.

“The additional resources that the University of Calgary is providing to MagicMed complement and enhance our strengths,” says Dr. Joseph Tucker, CEO MagicMed. “This collaboration places MagicMed in a position to expand the breadth and depth of the psychedelic derivatives contained in the MagicMed PsybraryTM.”

Click here to receive and investor presentation and corporate updates

Psybrary’s Unique Business Model

MagicMed’s team has been creating and patenting new molecular derivatives over the past 25 years with a focus on opiates, cannabinoids and ephedra. In particular, Chief Scientific Officer Dr. Peter Facchini is a recognized leader in the development of new molecular derivatives with over 160 scientific papers and 20 patents in the field.

MagicMed’s Place within the Process – Source: Investor Presentation

The PsybraryTM forms the basis of a unique business model capable of generating high-margin recurring revenue over time. By licensing derivative molecules, the company plans to generate licensing fees, milestone payments and blue-sky royalties when commercial products are launched into the market—all with minimal capital expenditures.

In addition to high margin revenue, the company works with a number of commercialization partners, which provides built-in diversification. Investors don’t have to bet all of their money on the success of one clinical trial, but rather, invest in a number of clinical trials run by partners where MagicMed retains the potential for royalty income.

Click here to receive and investor presentation and corporate updates

Looking Ahead

MagicMed Industries has shortcut its commercialization timeline with University of Calgary agreement. Over the next year, the company plans to expand its PsybraryTM with new patent filings, onboard its first partner, achieve a positive cash flow and publicly list during the first or second quarter—enabling retail investors to participate in the upside potential.

Investors may want to keep an eye on the company as it gears up for a public listing due to its multiple indications, partnership strategies, de-risked revenue model with blue sky potential and its conservative capital markets strategy geared toward generating near-term positive cash flow and long-term shareholder value.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.